Satoshi Kunitada

2.2k total citations
41 papers, 1.8k citations indexed

About

Satoshi Kunitada is a scholar working on Cardiology and Cardiovascular Medicine, Hematology and Internal Medicine. According to data from OpenAlex, Satoshi Kunitada has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Cardiology and Cardiovascular Medicine, 20 papers in Hematology and 8 papers in Internal Medicine. Recurrent topics in Satoshi Kunitada's work include Blood Coagulation and Thrombosis Mechanisms (20 papers), Atrial Fibrillation Management and Outcomes (18 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Satoshi Kunitada is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (20 papers), Atrial Fibrillation Management and Outcomes (18 papers) and Venous Thromboembolism Diagnosis and Management (8 papers). Satoshi Kunitada collaborates with scholars based in Japan, United States and Canada. Satoshi Kunitada's co-authors include Masaya Tachibana, Jeanne Mendell, Tsuyoshi Hara, Toshihiro Oguma, Hiroshi Masumoto, Masazumi Kojima, Jeanne Mendell‐Harary, Y Morishima, Indravadan Patel and Shashank Rohatagi and has published in prestigious journals such as Circulation, Blood and Journal of the American College of Cardiology.

In The Last Decade

Satoshi Kunitada

41 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Kunitada Japan 20 1.3k 893 509 177 105 41 1.8k
Michael Zuehlsdorf Germany 15 1.9k 1.5× 1.6k 1.8× 536 1.1× 256 1.4× 89 0.8× 25 2.3k
Margareta Elg Sweden 16 698 0.5× 581 0.7× 475 0.9× 286 1.6× 87 0.8× 32 1.3k
M. Urooj Zafar United States 22 754 0.6× 291 0.3× 206 0.4× 442 2.5× 53 0.5× 60 1.5k
Ma Luisa Suárez‐Gea Spain 15 600 0.5× 506 0.6× 87 0.2× 137 0.8× 30 0.3× 26 931
Heather M. Judge United Kingdom 22 887 0.7× 351 0.4× 335 0.7× 326 1.8× 28 0.3× 41 1.3k
Lars Wallentin Sweden 20 1.8k 1.4× 619 0.7× 80 0.2× 183 1.0× 20 0.2× 47 2.2k
Stefan Carlsson Sweden 14 401 0.3× 330 0.4× 230 0.5× 216 1.2× 39 0.4× 22 809
Róbert Gábor Kiss Hungary 17 1.2k 0.9× 357 0.4× 96 0.2× 443 2.5× 31 0.3× 93 1.7k
Francesco Franchi United States 31 2.4k 1.8× 648 0.7× 146 0.3× 1.2k 6.9× 54 0.5× 104 2.8k
Mariateresa Pugliano Italy 12 361 0.3× 181 0.2× 464 0.9× 123 0.7× 123 1.2× 22 868

Countries citing papers authored by Satoshi Kunitada

Since Specialization
Citations

This map shows the geographic impact of Satoshi Kunitada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Kunitada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Kunitada more than expected).

Fields of papers citing papers by Satoshi Kunitada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Kunitada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Kunitada. The network helps show where Satoshi Kunitada may publish in the future.

Co-authorship network of co-authors of Satoshi Kunitada

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Kunitada. A scholar is included among the top collaborators of Satoshi Kunitada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Kunitada. Satoshi Kunitada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shimizu, Takako, et al.. (2015). Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers. Thrombosis Research. 135(4). 594–601. 1 indexed citations
2.
Mendell, Jeanne, Helen Kastrissios, Michelle Green, et al.. (2012). Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thrombosis and Haemostasis. 107(5). 925–934. 107 indexed citations
3.
Samama, M, Jeanne Mendell, Céline Guinet, Léna Le Flem, & Satoshi Kunitada. (2011). In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thrombosis Research. 129(4). e77–e82. 54 indexed citations
4.
Patel, Indravadan, Daniel E. Salazar, Shashank Rohatagi, et al.. (2010). Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis. 104(9). 633–641. 260 indexed citations
5.
6.
Mendell‐Harary, Jeanne, Masaya Tachibana, Hiroshi Masumoto, et al.. (2010). Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers. The Journal of Clinical Pharmacology. 50(7). 743–753. 348 indexed citations
7.
Becker, Richard C., John H. Alexander, Youfu Li, et al.. (2004). Vascular Endothelial Tissue Factor Pathway Inhibitor Kinetics in Culture Following Exposure to DX-9065a—A Selective and Direct Factor Xa Inhibitor. Journal of Thrombosis and Thrombolysis. 18(3). 193–197. 2 indexed citations
8.
Alexander, John H., Christopher K. Dyke, Richard C. Becker, et al.. (2002). Initial experience with a novel direct factor Xa inhibitor in percutaneous coronary intervention. Journal of the American College of Cardiology. 39. 73–73. 1 indexed citations
9.
Iba, Toshiaki, et al.. (2002). Factor Xa-Inhibitor (Dx-9065a) Modulates the Leukocyte-Endothelial Cell Interaction in Endotoxemic Rat. Shock. 17(2). 159–162. 30 indexed citations
10.
Kaiser, Brigitte, et al.. (2000). A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats. Thrombosis Research. 98(2). 175–185. 20 indexed citations
11.
Murayama, Nobuyuki, Makoto Tanaka, Satoshi Kunitada, et al.. (1999). Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. Clinical Pharmacology & Therapeutics. 66(3). 258–264. 43 indexed citations
12.
Tanabe, Kiyoshi, Yasuko Terada, Tomoko Shibutani, Satoshi Kunitada, & Takashi Kondo. (1999). A Specific Inhibitor of Factor Xa, DX-9065a, Exerts Effective Protection against Experimental Tumor-Induced Disseminated Intravascular Coagulation in Rats. Thrombosis Research. 96(2). 135–143. 12 indexed citations
13.
Fukuda, Toshio, Tsuyoshi Hara, Kiyoshi Tanabe, & Satoshi Kunitada. (1997). Beneficial effect of DX-9065a, a direct and selective factor Xa inhibitor against experimental disseminated intravascular coagulation. Thrombosis and Haemostasis. 2527. 1 indexed citations
14.
Maeda, Mitsuko, et al.. (1996). Amino Acids and Peptides. XXVII. Solid Phase Synthesis of Fibrinogen-Related Peptides with Disulfide Bond Formed on Solid Support.. Chemical and Pharmaceutical Bulletin. 44(5). 1107–1110. 2 indexed citations
15.
Hara, Tsuyoshi, et al.. (1995). Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thrombosis Research. 80(1). 99–104. 62 indexed citations
16.
Nagahara, Takayasu, Yukio Yokoyama, Satoshi Komoriya, et al.. (1995). DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITIES OF ORALLY ACTIVE COAGULATION FACTOR Xa INHIBITORS. European Journal of Medicinal Chemistry. 30. 139s–143s. 10 indexed citations
17.
Kunitada, Satoshi, et al.. (1992). A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. European Journal of Pharmacology. 210(2). 163–172. 15 indexed citations
18.
Kunitada, Satoshi, et al.. (1992). Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood. 79(6). 1420–1427. 8 indexed citations
19.
Kerins, David, et al.. (1991). A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction.. Journal of Pharmacology and Experimental Therapeutics. 257(1). 487–492. 10 indexed citations
20.
Kunitada, Satoshi, et al.. (1991). A thromboxane A2 synthase inhibitor, DP-1904, prevents rat renal injury. European Journal of Pharmacology. 193(3). 321–327. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Zuehlsdorf Breakdown of academic impact, for papers by Margareta Elg Breakdown of academic impact, for papers by M. Urooj Zafar Breakdown of academic impact, for papers by Ma Luisa Suárez‐Gea Breakdown of academic impact, for papers by Heather M. Judge Breakdown of academic impact, for papers by Lars Wallentin Breakdown of academic impact, for papers by Stefan Carlsson Breakdown of academic impact, for papers by Róbert Gábor Kiss Breakdown of academic impact, for papers by Francesco Franchi Breakdown of academic impact, for papers by Mariateresa Pugliano
Rankless by CCL
2026